• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
DMAC

DMAC

DiaMedica Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS

USD5.65

-0.12 (-2.08%)

Rating:C

Company Profile

CEO

Dietrich John Pauls

IPO Date

2012-08-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.72

Prev. Close

$5.77

Day Low

$5.62

Day High

$5.86

52W Low

$3.48

52W High

$10.42

Market Cap

$0.30B

Volume

0.18M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

24.2%

Avg Negative

25.5%

Avg Neutral

50.4%

News Feed

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/12/2021·↓ negative

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results

Business Wire·8/11/2021·↑ positive

DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021

Business Wire
·8/5/2021
·↓ negative

Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)

Zacks Investment Research·7/14/2021·↓ negative

DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients

Benzinga·6/29/2021·↑ positive

DMAC Stock Price Falls Over 25% Pre-Market: Why It Happened

Pulse2·6/29/2021·↓ negative

DiaMedica: Undercovered Stroke Drug Company With Decent Data

Seeking Alpha·6/13/2021·↓ negative

Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?

Zacks Investment Research·5/26/2021·↓ negative

DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke

Benzinga·5/17/2021·↑ positive

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

Business Wire·5/17/2021·↑ positive